| news releases |
| Back | Print | Bookmark |
|
Mentor Capital, Inc. Speaks on Cancer Investment with Long Island Investment Banking Group |
| |
|
San Diego, CA--September 30, 2009--Mentor Capital, Inc. (Pink Sheets:MNTR) CEO, Chet Billingsley, presented an
update of Mentor Capital's rapid progress in advancing its cancer immunotherapy efforts before the Long Island
Investment Banking Group. The gathered investment bankers and brokers represented approximately $2 Billion in
Assets Under Management and are a major conduit for emerging companies to access the brokerage community.
Mr. Billingsley highlighted the sea change in cancer treatment coming from the immunotherapy sector, which was
validated by Dendreon's (DNDN) positive FDA announcement and 1,000% stock rise in March 2009. Both Dendreon, for
prostate cancer, and Mentor Capital, for breast cancer, use the same dendritic immunotherapy approach, only with
different target cancer surface proteins. In cancer immunotherapy, instead of chemotherapy, surgeries and
radiation, the body’s own immune system is triggered to attack cancer cells. Patients report only flu-like symptoms
as their now activated natural defenses attempt to eradicate or stabilize the targeted cancers.
Both Dendreon and Mentor Capital are prominent in the Cancer Immunotherapy Index. The CI Index is projected to
experience an 1100% growth if the total sector projected value keeps pace with the projected sector revenue.
Mentor Capital is a major investor in the Florida based private company, Quantum Immunologics, now in Phase I/II
FDA trials for their breast cancer immunotherapy treatment. Additional information on Mentor Capital, and Quantum
Immunologics may be referenced at the company website: www.MentorCapital.com.
Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company
web site.
__________
Chet Billingsley is the CEO and Chairman of Mentor Capital, Inc. Mentor Capital, Inc. invests in leading-edge
cancer companies across all companies in its proprietary Cancer Immunotherapy Index and seeks to overweight
acquisition or stock purchase funding in those companies with the greatest promise.
Chet Billingsley, CEO
Mentor Capital, Inc.
P.O. Box 1709
Ramona, CA 92065
(760) 788-4700
↑ Back to Top
|